AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04199988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior Shoulder Endurance Test
Description: Isometric posterior shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction, and the time for maintaining this position will be recorded.~Isotonic shoulder endurance test: In the prone position, the athlete's shoulder will be placed at horizontal abduction and asked to perform horizontal adduction-abduction, and the athlete will horizontally abducted-adducted his/her arm to 90 degrees at a cadence of 30 beats per minute. The number of repetitions will be recorded.
Study NCT02425852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine alone versus Azathioprine and IFX
Study NCT02425852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Study NCT02425852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Study NCT02425852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Study NCT03859310 — intervention group
Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
Study NCT03475836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mentha piperita
Description: Commercially available essential oil suspended in an off-the-shelf vegetable oil.
Study NCT03475836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
Study NCT01962740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent implantation
Study NCT01931293 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic
Description: Vitamin Supplement therapy
Study NCT01771224 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid
Description: Palmitoleic acid and 5-ASA
Study NCT05188833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
Study NCT05188833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Transcranial Magnetic Stimulation
Description: Deep TMS, unlike traditional TMS, is a treatment method that provides stimulation of lower parts of the brain and larger brain volume, in addition to drug treatment and psychotherapy approaches, in addition to localized brain regions magnetic stimulation is a treatment method where disease symptoms are addressed.
Study NCT05188833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
Study NCT05188833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine
Description: Paroxetine is a type of antidepressant known as an SSRI (selective serotonin reuptake inhibitor). It's often used to treat depression.
Study NCT03240549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
Study NCT02392819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Description: Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
Study NCT02392819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00915382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 and cisplatin
Description: S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1
Study NCT00915382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1 and cisplatin
Description: S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8
Study NCT01570946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
Study NCT04625504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
Study NCT00473239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol.
Description: 100,000 IU of Vitamin D
Study NCT03527459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPARC B
Description: SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
Study NCT03527459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARC A
Description: SPARC A is an existing clinical program with a general focus on negative cognitions.
Study NCT00364104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple sequential Helicobacter pylori eradication + iron sulfate
Description: A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
Study NCT00364104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple sequential Helicobacter pylori eradication therapy
Description: A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
Study NCT00364104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
Study NCT00364104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
Study NCT04626908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC022F CAR-T cells
Description: Each subject receive GC022F CAR-T cells by intravenous infusion
Study NCT01608945 — intervention group
Intervention type: DRUG
Intervention: Hydrocortisone sodium succinate
Description: 100mg/day
Study NCT02442388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with hand file
Description: type of instrumentation technique for root canal treatment
Study NCT02442388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with ProTaper
Description: type of instrumentation technique for root canal treatment
Study NCT02442388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Instrumentation technique with WaveOne
Description: type of instrumentation technique for root canal treatment
Study NCT03674905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intra-articular injection
Description: Intra-articular injection at the completion of TAA procedure.
Study NCT03674905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral nerve block
Description: Pre-operative peripheral nerve block.
Study NCT01150188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Amino acids
Description: 11 g amino acids two times per day for eight weeks
Study NCT01150188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of inert compounds, 11 g two times per day for eight weeks
Study NCT04113421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced chest CT
Description: A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
Study NCT01872390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Intervention Package
Description: CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
Study NCT01872390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
Study NCT00781703 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DIAMOND depression care model
Description: Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
Study NCT02462096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLeaf
Description: The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Study NCT03053167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
Study NCT03053167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
Study NCT01734603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental rehabilitation program
Description: Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~* Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~* Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~* Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% .
Study NCT01734603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation program
Description: Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible.
Study NCT00804908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: temozolomide capsule administered orally once daily for 5 days every 28 days
Study NCT00804908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: temozolomide
Description: temozolomide capsule administered orally once daily for 5 days every 28 days
Study NCT00804908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-888
Description: ABT-888 capsule administered orally twice daily for 7 days every 28 days
Study NCT00804908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
Study NCT01955330 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic Hybrid coronary artery revascularization
Description: Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
Study NCT04550429 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyoSure Hysteroscopic Morcellator Device
Description: This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
Study NCT04550429 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MyoSure Hysteroscopic Morcellator Device
Description: This device is normally used for this procedure, but I included it as intervention because we will lower the pressure for one arm of the study (treatment) and keep the pressure in the other arm (control) as the standard of care.
Study NCT02724618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
Study NCT02724618 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Study NCT02724618 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: RT
Description: EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
Study NCT02724618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
Study NCT02433808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine Group
Description: Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
Study NCT02433808 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Neostigmine group
Description: Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
Study NCT05467969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Teleteaching of procedural skills through the online multiscreen display teleconference platform
Description: Teleteaching of procedural skills include three different techniques through three different workshops. Each of the workshops was delivered by a respected expert faculty and then accompanied by skills assessment subsequently. Three different group of learners joined the workshops on knotting skills, suturing skills and laparoscopic hand-eye coordination skills respectively.
Study NCT04228380 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05795608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: respiratory exercise with incentive spirometry
Description: Subjects in the intervention group were trained to perform 15 minutes of respiratory exercise with incentive spirometry four times a day for two days before surgery by trained medical personnel. First, subjects were instructed to make a good seal over the incentive spirometry mouthpiece with their lips. Afterward, they were asked to inhale deeply and slowly, and they were also directed to hold their breath at the end of inspiration
Study NCT03762993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocal rest and Controlled Phonation
Description: Voice rest and semi occluded vocal tract voice exercises
Study NCT05002712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy resistance training
Description: Their training program included 4 resistance exercises with heavy weight lifting of the leg muscles. 3 sets of 6-8 repetitions of 80-90 % of maximal load were performed with a barbell squat (range of 0 to 90º knee flexion), lying leg curl, seated calf raises, and leg extension. The rests between the sets and the exercises lasted 5 minutes.
Study NCT05002712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast strength training
Description: Their resistance training program contained the same exercises as the high resistance training group, but with different intensity. Athlete performed each exercise for the first time with 5-7 reps with 80 % of the 1RM load followed by 15-20 reps with 40 % of the maximal load to complete the 3 sets for each exercise. The rest period between series was 60 seconds and the rest period between exercises was 5 minutes. For example, 5 heavy barbell squats followed immediately by 20 squat with lighter weight to complete 3 sets.
Study NCT05002712 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic resistance training
Description: During the intervention, the group conducted a 'elastic resistance training' with the same muscle groups. External resistance was provided by blue thera-band latex-free exercise bands in this training. Each exercise was performed three times for a total of 15-25 repetitions. In between sets, a 5-minute rest period was given and there was a 25-second rest period in between exercise performance. The intensity of each exercise was increased with the black thera band at the midpoint (start of week 7) of the training. The following figure shows the resistance of the blue and black bands to 100 percent elongation. Following figure shows the resistance offered by blue and black band at 100% elongation.
Study NCT00404144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon
Description: PCI of small vessels single arm study
Study NCT02564003 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Description: oxycodone 0,1 mg/kg iv
Study NCT03819114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Description: LNG tablet(s) were administered by mouth in a directly observed manner.
Study NCT02572102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Energy Drink, two 16oz containers consumed in 45 minutes
Study NCT02572102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panax Ginseng
Description: Panax Ginseng, lime juice, water and cherry flavoring
Study NCT02572102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lime juice, water and cherry flavoring
Study NCT01263847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide
Description: Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Study NCT01263847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Galactooligosaccharide
Description: Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Study NCT03531346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily-disposable soft contact lens
Description: Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
Study NCT03900091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex PCR assay for meningitis
Description: CSF from cases to be analysed with a FilmArray ME Panel
Study NCT03900091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex vertical flow microarrray assay for meningitis
Description: CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
Study NCT03900091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Profiling of blood proteins by multi-analyte Profiling technology
Description: Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
Study NCT03900091 — intervention group
Intervention type: OTHER
Intervention: Typing and whole genome sequencing
Description: Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .